Development and design of bio-pharmaceutical processes

Current Opinion in Chemical Engineering

Volumn 2, Issue 4, 2013, Pages 435-441

  Kontoravdi, Cleo ^a   Samsatli, Nouri J ^a   Shah, Nilay ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRODUCTION PLATFORMS;

BIO PHARMACEUTICALS; JAPANESE REGULATORY AGENCY; PETROCHEMICALS INDUSTRY; PHARMACEUTICAL PRODUCTS; PHARMACEUTICAL SECTOR; PROCESS ANALYTICAL TECHNOLOGY; PROCESS SYSTEMS ENGINEERING; THERAPEUTIC PRODUCTS;

PRODUCT DESIGN;

EID: 84899980062     PISSN: None     EISSN: 22113398     Source Type: Journal    
DOI: 10.1016/j.coche.2013.09.007     Document Type: Review

References (40)

1. Kyriakopoulos S, Kontoravdi C: Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends. Eur J Pharmaceut Sci 2012, 48:428-441.
2. Pharmaceutical Development Q8(R2) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Quality/Q8-R1/ Step4/Q8-R2-Guideline.pdf.
3. Rathore AS, Winkle H: Quality by design for biopharmaceuticals. Nat Biotechnol 2009, 27:26-34.
4. Orlandini S, Pinzauti S, Furlanetto S: Application of quality by design to the development of analytical separation methods. Anal Bioanal Chem 2013, 405:443-450.
5. Bilsel RU, Lin DKJ: Ishikawa cause and effect diagrams using capture recapture techniques. Qual Technol Quantit Manage 2012, 9:137-152.
6. Yu LX: Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 2008, 25:781-791.
7. Troup GM, Georgakis C: Process systems engineering tools in the pharmaceutical industry. Comput Chem Eng 2013, 51:157-171.
8. Hogwood CEM, Tait AS, Koloteva-Levine N, Bracewell DG, Smales CM: The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process. Biotechnol Bioeng 2013, 110:240-251.
9. Tait AS, Tarrant RDR, Velez-Suberbie ML, Spencer DIR, Bracewell DG: Differential response in downstream processing of CHO cells grown under mild hypothermic conditions. Biotechnol Progress 2013.
10. Fisher RA: The Design of Experiments. Oxford, England: Oliver & Boyd; 1935, .
11. Eon-Duval A, Valax P, Solacroup T, Broly H, Gleixner R, Le Strat C, Sutter J: Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: towards a global multi-step design space. J Pharm Sci 2012, 101:3604-3618.
12. Bibila TA, Flickinger MC: Use of a structured kinetic-model of antibody-synthesis and secretion for optimization of antibody-production systems. 2. Transient analysis. Biotechnol Bioeng 1992, 39:262-272.
13. Bibila TA, Robinson DK: In pursuit of the optimal fed-batch process for monoclonal-antibody production. Biotechnol Progress 1995, 11:1-13.
14. Dhir S, Morrow KJ, Rhinehart RR, Wiesner T: Dynamic optimization of hybridoma growth in a fed-batch bioreactor. Biotechnol Bioeng 2000, 67:197-205. (Pubitemid 30029781)
15. Fox SR, Patel UA, Yap MGS, Wang DIC: Maximizing interferon- gamma production by Chinese hamster ovary cells through temperature shift optimization: experimental and modeling. Biotechnol Bioeng 2004, 85:177-184. (Pubitemid 38141119)
16. Craven S, Shirsat N, Whelan J, Glennon B: Process model comparison and transferability across bioreactor scales and modes of operation for a mammalian cell bioprocess. Biotechnol Progress 2013, 29:186-196.
17. Nolan RP, Lee K: Dynamic model of CHO cell metabolism. Metab Eng 2011, 13:108-124.
18. Selvarasu S, Ho YS, Chong WPK, Wong NSC, Yusufi FNK, Lee YY, Yap MGS, Lee DY: Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO cell culture. Biotechnol Bioeng 2012, 109:1415-1429.
19. Mantzaris NV, Daoutidis P: Cell population balance modeling and control in continuous bioreactors. J Process Control 2004, 14:775-784.
20. Fernandes RL, Nierychlo M, Lundin L, Pedersen AE, Tellez PEP, Dutta A, Carlquist M, Bolic A, Schapper D, Brunetti AC et al.: Experimental methods and modeling techniques for description of cell population heterogeneity. Biotechnol Adv 2011, 29:575-599.
21. Jimenez del Val I, Nagy JM, Kontoravdi C: A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus. Biotechnol Prog 2011, 27:1730-1743.
22. Gerontas S, Shapiro MS, Bracewell DG: Chromatography modelling to describe protein adsorption at bead level. J Chromatogr A 2013, 1284:44-52.
23. Mollerup JM, Hansen TB, Kidal S, Staby A: Quality by design - thermodynamic modelling of chromatographic separation of proteins. J Chromatogr A 2008, 1177:200-206. (Pubitemid 350299029)
24. Pollock J, Bolton G, Coffman J, Ho SV, Bracewell DG, Farid SS: Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J Chromatogr A 2013, 1284:17-27.
25. Stonier A, Pain D, Westlake A, Hutchinson N, Thornhill NF, Farid SS: Integration of stochastic simulation with multivariate analysis: short-term facility fit prediction. Biotechnol Progress 2013, 29:368-377.
26. Muller-Spath T, Strohlein G, Aumann L, Kornmann H, Valax P, Delegrange L, Charbaut E, Baer G, Lamproye A, Johnck M et al.: Model simulation and experimental verification of a cation-exchange IgG capture step in batch and continuous chromatography. J Chromatogr A 2011, 1218:5195-5204.
27. Guelat B, Strohlein G, Lattuada M, Delegrange L, Valax P, Morbidelli M: Simulation model for overloaded monoclonal antibody variants separations in ionexchange chromatography. J Chromatogr A 2012, 1253:32-43.
28. Polykarpou EM, Dalby PA, Papageorgiou LG: An MILP formulation for the synthesis of protein purification processes. Chem Eng Res Des 2012, 90:1262-1270.
29. Getaz D, Butte A, Morbidelli M: Model-based design space determination of peptide chromatographic purification processes. J Chromatogr A 2013, 1284:80-87.
30. Global Vaccine Market Forecast to 2017. http:// www.researchandmarkets. com/research/jdxsk3/global-vaccine.
31. Rimmelzwaan GF, Osterhaus ADME: Influenza vaccines: new developments. Curr Opin Pharmacol 2001, 1:491-496. (Pubitemid 33593838)
32. Voudouris VT, Grossmann IE: MILP model for scheduling and design of a special class of multipurpose batch plants. Comput Chem Eng 1996, 20:1335-1360.
33. Samsatli NJ, Shah N: An optimization based design procedure for biochemical processes. 1. Preliminary design and operation. Food Bioprod Process 1996, 74:221-231.
34. Tsang KH, Samsatli NJ, Shah N: Modelling and planning optimization of a complex flu vaccine facility. Food Bioprod Process 2006, 84:123-134. (Pubitemid 43978146)
35. Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, Bobrowicz P, Stadheim TA, Li H, Choi B-K et al.: Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006, 313:1441-1443. (Pubitemid 44360273)
36. Doran PM: Foreign protein production in plant tissue cultures. Curr Opin Biotechnol 2000, 11:199-204. (Pubitemid 30182316)
37. Kitney R, Freemont P: Synthetic biology - the state of play. FEBS Lett 2012, 586:2029-2036.
38. Shaping the Biosimilars Opportunity: A Global Perspective on the Evolving Biosimilars Landscape. http://www.imshealth.com/ims/ Global/Content/ Home%20Page%20Content/IMS%20News/ Biosimilars-Whitepaper.pdf.
39. Doneanu CE, Xenopoulos A, Fadgen K, Murphy J, Skilton SJ, Prentice H, Stapels M, Chen WB: Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online twodimensional liquid chromatography/mass spectrometry. mAbs 2012, 4:24-44.
40. Mittermayr S, Bones J, Doherty M, Guttman A, Rudd PM: Multiplexed analytical glycomics: rapid and confident IgG N-glycan structural elucidation. J Proteome Res 2011, 10:3820-3829.